NEW YORK (GenomeWeb News) – Brahms subsidiary Cezanne will incorporate technology from Lumiphore in its diagnostic tests under two new agreements, Richmond, Calif.-based Lumiphore said today.

Brahms and Cezanne will use the Lumi4-Tb technology in development of current and future diagnostic tests under a non-exclusive agreement. In addition, Cezanne acquired exclusive rights to use the technology in diagnostic tests for Down's Syndrome, including tests for Trisomy 21, 13 and 18, Triploidy, Translocation, and Mosaicism, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.